Sanofi (NYSE:SNY) announced today that it agreed to acquire all outstanding shares of Principia Biopharma (NSDQ:PRNB) in a deal worth approximately $3.68 billion. The deal sets all outstanding shares of Principia at $100 per share, which will be acquired in cash. Sanofi and Principia both received unanimous approval from their respective boards of directors, according to […]
Sanofi
MedTech 100 roundup: Industry hits another mid-pandemic high
Despite a minor regression week-over-week, the medtech industry’s stocks hit another milestone as the COVID-19 rebound remains in progress. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.01 points at the end of last week (July 31). Overall, medtech stocks saw a -0.3% increase from the […]
GSK, Sanofi land $2.1B from feds to develop COVID-19 vaccine
The Trump administration has awarded Sanofi (NYSE:SNY) and GlaxoSmithKline (NYSE:GSK) a contract for up to $1.2 billion to develop, manufacture and deliver a vaccine for COVID-19, the companies announced today. The vaccine candidate is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established pandemic adjuvant (immunity-boosting) technology. Manufacturing will take […]
Baxter completes Seprafilm acquisition
Baxter (NYSE:BAX) today said it completed the acquisition of Seprafilm Adhesion Barrier and its assets from Sanofi in a deal worth $350 million. Seprafilm is used as an adjunct to reduce the incidence, extent and severity of adhesions in pelvic and abdominal surgeries, according to the company. It is commercially available in the U.S., Japan, […]
FDA clears Verily Study Watch for additional capabilities
Verily, Google’s life science’s sister company under Alphabet (NSDQ:GOOGL), has received an FDA 510(k) clearance to include an irregular pulse monitor in its Study Watch wearable. The FDA announcement, last updated Jan. 20, did not include additional information. The agency cleared ECG capabilities on the Study Watch in January 2019. Launched in April 2017, the Study […]
Baxter rises after Street-beating preliminary 4Q sales results
Baxter (NYSE:BAX) shares were up today after the company reported preliminary net sales for the fourth quarter of fiscal 2019 that topped the Wall Street consensus. The Deerfield, Ill.-based company posted net sales of $3 billion for the fourth quarter, marking 7% growth on a reported basis and 9% growth on an operational basis. That number […]
Sanofi eyes Synthrox purchase
Sanofi (NYSE:SNY) announced today that it is planning to tender an offer to acquire all outstanding common stock shares of clinical-stage biotech company Synthorx. The agreement and plan of merger between the two companies was announced on Dec. 7 and the offer is being made pursuant to that. Sanofi said it stands to acquire the common […]
Sanofi backs away from diabetes partnership with Verily
Three years after investing $248 million in a Type 2 diabetes joint venture with Google’s (NSDQ:GOOGL) Verily Life Sciences, , Sanofi (NYSE:SNY) is backing out. The drug company’s new CEO made the announcement during a capital markets meeting yesterday, saying the company had over-invested in the virtual diabetes clinic, Onduo, according to published reports. Sanofi will […]
Baxter spending $350m to acquire surgical adhesion barrier tech from Sanofi
Baxter (NYSE:BAX) said today that it will buy the Seprafilm adhesion barrier and related assets from Sanofi (NYSE:SNY) in what is expected to be a $350 million deal. The purchase is expected to close no later than the first quarter of 2020. A Bloomberg report in October hinted that a deal might be in the work. “While […]
Sanofi, Aetion collaborate to advance regulatory submissions
Sanofi (NYSE:SNY) announced today that it entered into a collaboration with Aetion to integrate its Darwin data platform with the Aetion Evidence platform to try and advance the efficiency of real-world evidence. The collaboration between the two companies will set out to facilitate regulatory-grade studies with deep transparency while opening access to new real-world data, according […]
Report: Sanofi is shopping SepraFilm unit to Baxter
Sanofi (NYSE:SNY) is said to be in advanced talks with BAX to sell its Seprafilm surgical products business for up to $400 million. SepraFilm is designed to prevent adhesion after abdominal surgeries. The French drugmaker, which acquired SepraFilm in 2011 when it paid $20.1 billion for Genzyme, wants to close the deal “with the next few […]
